Neda Rasouli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7788554/publications.pdf

Version: 2024-02-01

86 papers	6,557 citations	76196 40 h-index	62479 80 g-index
87 all docs	87 docs citations	87 times ranked	9482 citing authors

#	Article	IF	Citations
1	Adipocytokines and the Metabolic Complications of Obesity. Journal of Clinical Endocrinology and Metabolism, 2008, 93, s64-s73.	1.8	597
2	Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 520-530.	13.9	423
3	Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E1016-E1027.	1.8	363
4	Expression of CD68 and Macrophage Chemoattractant Protein-1 Genes in Human Adipose and Muscle Tissues: Association With Cytokine Expression, Insulin Resistance, and Reduction by Pioglitazone. Diabetes, 2005, 54, 2305-2313.	0.3	331
5	OXPAT/PAT-1 Is a PPAR-Induced Lipid Droplet Protein That Promotes Fatty Acid Utilization. Diabetes, 2006, 55, 3418-3428.	0.3	276
6	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	5.5	244
7	Endoplasmic Reticulum Stress Markers Are Associated with Obesity in Nondiabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4532-4541.	1.8	243
8	Adipose Tissue Extracellular Matrix and Vascular Abnormalities in Obesity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1990-E1998.	1.8	226
9	Retinol Binding Protein 4 Expression in Humans: Relationship to Insulin Resistance, Inflammation, and Response to Pioglitazone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2590-2597.	1.8	200
10	Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E1300-E1310.	1.8	181
11	Human Visfatin Expression: Relationship to Insulin Sensitivity, Intramyocellular Lipids, and Inflammation. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 666-672.	1.8	179
12	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	4.3	177
13	Thrombospondin-1 Is an Adipokine Associated With Obesity, Adipose Inflammation, and Insulin Resistance. Diabetes, 2008, 57, 432-439.	0.3	159
14	The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. Journal of Lipid Research, 2006, 47, 2444-2450.	2.0	150
15	Oxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunction. International Journal of Biochemistry and Cell Biology, 2006, 38, 794-803.	1.2	138
16	Adipose Tissue Hypoxia, Inflammation, and Fibrosis in Obese Insulin-Sensitive and Obese Insulin-Resistant Subjects. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1422-1428.	1.8	136
17	Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action. Diabetes Care, 2013, 36, 1807-1814.	4.3	134
18	Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E930-E934.	1.8	123

#	Article	IF	Citations
19	Ectopic fat accumulation and metabolic syndrome. Diabetes, Obesity and Metabolism, 2007, 9, 1-10.	2.2	123
20	Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E1100-E1105.	1.8	112
21	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	4.3	109
22	Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E42-E46.	1.8	102
23	Lipin Expression Is Attenuated in Adipose Tissue of Insulin-Resistant Human Subjects and Increases With Peroxisome Proliferator-Activated Receptor Â Activation. Diabetes, 2006, 55, 2811-2818.	0.3	97
24	Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia, 2007, 50, 1621-1630.	2.9	91
25	Global Gene Expression Profiles of Subcutaneous Adipose and Muscle From Glucose-Tolerant, Insulin-Sensitive, and Insulin-Resistant Individuals Matched for BMI. Diabetes, 2011, 60, 1019-1029.	0.3	91
26	The Effects of Temperature and Seasons on Subcutaneous White Adipose Tissue in Humans: Evidence for Thermogenic Gene Induction. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2772-E2779.	1.8	83
27	Subcutaneous Administration of Glargine to Diabetic Patients Receiving Insulin Infusion Prevents Rebound Hyperglycemia. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3132-3137.	1.8	81
28	The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance, Î²-cell function, and diabetes in Hispanics and African Americans. Journal of Diabetes and Its Complications, 2019, 33, 118-122.	1.2	71
29	Matrix Metalloproteinase-9 Is Increased in Obese Subjects and Decreases in Response to Pioglitazone. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2993-3001.	1.8	70
30	Stearoyl-Coenzyme A Desaturase 1 Gene Expression Increases after Pioglitazone Treatment and Is Associated with Peroxisomal Proliferator-Activated Receptor-Î³ Responsiveness. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4431-4439.	1.8	65
31	Pioglitazone induces apoptosis of macrophages in human adipose tissue. Journal of Lipid Research, 2006, 47, 2080-2088.	2.0	63
32	Divergent Effects of Peroxisome Proliferator-activated Receptor Î³ Agonists and Tumor Necrosis Factor Î± on Adipocyte ApoE Expression. Journal of Biological Chemistry, 2004, 279, 47626-47632.	1.6	58
33	Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882098022.	1.4	58
34	Comparison of 70/30 Biphasic Insulin With Glargine/Lispro Regimen in Nonâ€“Critically Ill Diabetic Patients on Continuous Enteral Nutrition Therapy. Nutrition in Clinical Practice, 2011, 26, 714-717.	1.1	56
35	Glycaemic efficacy and safety of linagliptin compared to a basalâ€bolus insulin regimen in patients with type 2 diabetes undergoing nonâ€cardiac surgery: A multicentre randomized clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 837-843.	2.2	53
36	Association of Scavenger Receptors in Adipose Tissue With Insulin Resistance in Nondiabetic Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1328-1335.	1.1	51

#	Article	IF	Citations
37	Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E393-E400.	1.8	50
38	Adipose triglyceride lipase expression in human adipose tissue and muscle. Role in insulin resistance and response to training and pioglitazone. Metabolism: Clinical and Experimental, 2011, 60, 1012-1020.	1.5	49
39	Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity. PLoS ONE, 2014, 9, e102190.	1.1	45
40	A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vascular Health and Risk Management, 2007, 3, 967-73.	1.0	41
41	Insulin Resistance in African-American and Caucasian Women: Differences in Lipotoxicity, Adipokines, and Gene Expression in Adipose Tissue and Muscle. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4441-4448.	1.8	39
42	Genetic Risk Factors for Type 2 Diabetes: A Trans-Regulatory Genetic Architecture?. American Journal of Human Genetics, 2012, 91, 466-477.	2.6	31
43	Impact of Glucose Management Team on Outcomes of Hospitalization in Patients With Type 2 Diabetes Admitted to the Medical Service. Endocrine Practice, 2016, 22, 1401-1405.	1.1	31
44	Impact of Family History of Diabetes and Ethnicity on Î²-Cell Function in Obese, Glucose-Tolerant Individuals. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4656-4663.	1.8	29
45	Adipose Tissue Hypoxia and Insulin Resistance. Journal of Investigative Medicine, 2016, 64, 830-832.	0.7	28
46	Effects of Short-Term Experimental Insulin Resistance and Family History of Diabetes on Pancreatic Î²-Cell Function in Nondiabetic Individuals. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5825-5833.	1.8	25
47	Calcium Is Involved in Formation of High Molecular Weight Adiponectin. Metabolic Syndrome and Related Disorders, 2008, 6, 103-111.	0.5	25
48	The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of Î²-cell function in African American women. Metabolism: Clinical and Experimental, 2015, 64, 561-565.	1.5	25
49	Endocrinology Telehealth Consultation Improved Glycemic Control Similar to Face-to-Face Visits in Veterans. Journal of Diabetes Science and Technology, 2016, 10, 1079-1086.	1.3	25
50	Improved insulin sensitivity after treatment with PPARÎ³ and PPARÎ± ligands is mediated by genetically modulated transcripts. Pharmacogenetics and Genomics, 2012, 22, 484-497.	0.7	24
51	Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 230-240.	1.8	24
52	The prevention and treatment of metabolic syndrome and high-risk obesity. Current Opinion in Cardiology, 2006, 21, 479-485.	0.8	23
53	Effects of pioglitazone and metformin on Î²-cell function in nondiabetic subjects at high risk for type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E359-E365.	1.8	22
54	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e130-e138.	1.8	22

#	Article	IF	Citations
55	Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2767-2778.	1.8	20
56	Cystic Fibrosis-Related Diabetes in Adults: Inpatient Management of 121 Patients during 410 Admissions. Journal of Diabetes Science and Technology, 2012, 6, 1038-1044.	1.3	18
57	Integrative mRNA-microRNA analyses reveal novel interactions related to insulin sensitivity in human adipose tissue. Physiological Genomics, 2016, 48, 145-153.	1.0	18
58	Improved Glycemic Control in Subjects with Atypical Diabetes Results from Restored Insulin Secretion, But Not Improved Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6331-6335.	1.8	16
59	Professional Practice Committee. Diabetes Care, 2014, 37, S1-S1.	4.3	16
60	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care, 2018, 41, 1590-1599.	4.3	16
61	Association of Baseline Characteristics With Insulin Sensitivity and Î²-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care, 2021, 44, 340-349.	4.3	16
62	Effect of Glargine Insulin Delivery Method (Pen Device Versus Vial/Syringe) on Glycemic Control and Patient Preferences in Patients with Type 1 and Type 2 Diabetes. Endocrine Practice, 2014, 20, 536-539.	1.1	14
63	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care, 2020, 43, 940-947.	4.3	14
64	Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. Journal of Diabetes and Its Complications, 2021, 35, 107733.	1.2	12
65	Shape of the OGTT glucose response curve: relationship with Î²-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Research and Care, 2021, 9, e002264.	1.2	12
66	An ACACB Variant Implicated in Diabetic Nephropathy Associates with Body Mass Index and Gene Expression in Obese Subjects. PLoS ONE, 2013, 8, e56193.	1.1	11
67	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished Î²-Cell Function in Patients With Type 2 Diabetes in the GRADE Study. Diabetes, 2022, 71, 1261-1271.	0.3	11
68	Management of Hemoglobin Variants Detected Incidentally in HbA1c Testing: A Common Problem Currently Lacking a Standard Approach. Diabetes Care, 2017, 40, e8-e9.	4.3	10
69	DHA reduces the atrophy-associated Fn14 protein in differentiated myotubes during coculture with macrophages. Journal of Nutritional Biochemistry, 2012, 23, 885-891.	1.9	9
70	Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1201-1209.	2.2	9
71	Peroxisome Proliferator-Activated Receptor Ligands as Antiatherogenic Agents: Panacea or Another Pandora's Box?. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 1-8.	1.0	8
72	Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation. Hormone and Metabolic Research, 2017, 49, 50-57.	0.7	8

#	Article	IF	Citations
73	Intermuscular lipid: a marker of disordered fat partitioning or the consequence of obesity?. American Journal of Clinical Nutrition, 2008, 87, 1585-1586.	2.2	6
74	Glycemic Control and Outcomes of Hospitalization in Noncritically Ill Patients With Type 2 Diabetes Admitted With Cardiac Problems or Infections. Endocrine Practice, 2014, 20, 1303-1308.	1.1	6
75	Reproducibility of a prediabetes classification in a contemporary population. Metabolism Open, 2020, 6, 100031.	1.4	6
76	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. Drugs, 2018, 78, 203-214.	4.9	5
77	Hyperoxia improves carbohydrate metabolism by browning of white adipocytes in obese type 2 diabetic rats. Life Sciences, 2019, 220, 58-68.	2.0	5
78	Association of glycemia with insulin sensitivity and Î²-cell function in adults with early type 2 diabetes on metformin alone. Journal of Diabetes and Its Complications, 2021, 35, 107912.	1.2	5
79	Led Astray by Hemoglobin A1c. Journal of Investigative Medicine High Impact Case Reports, 2016, 4, 232470961662854.	0.3	3
80	Serum lipid profile as a tool to predict incident diabetes: Is it a wishful thinking?. Journal of Diabetes and Its Complications, 2020, 34, 107755.	1.2	3
81	Matrix Metalloproteinase-9 Is Increased in Obese Subjects and Decreases in Response to Pioglitazone. Molecular Endocrinology, 2010, 24, 1106-1107.	3.7	2
82	Regulation of Small Ubiquitin-Like Modifier-1, Nuclear Receptor Coreceptor, Histone Deacetylase 3, and Peroxisome Proliferator-Activated Receptor-Î³ in Human Adipose Tissue. Metabolic Syndrome and Related Disorders, 2012, 10, 312-317.	0.5	2
83	The Effects of Temperature and Seasons on Subcutaneous White Adipose Tissue in Humans. Obstetrical and Gynecological Survey, 2015, 70, 180-181.	0.2	2
84	An Escape From Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3460-e3461.	1.8	2
85	Pathogenesis and Treatment of High-Risk Obesity. , 2006, , 48-63.		0
86	Response to Letter to the Editor from Chang Villacreses et al: â€œEffects of vitamin D supplementation on insulin sensitivity and secretion in prediabetes.â€• Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	0